

Curriculum Vitae

Dr. PRASHANT PANDEY

**MBBS, MD, DrNB (Medical Oncology), MRCP (UK, SCE Medical Oncology),
ECMO**

West Bengal Medical Council Reg. No: 60535

Mobile: +91-9804290687 | Email: prashantpandeydr@gmail.com

- **Current Position**
- **Consultant medical oncologist**
- **Tata medical centre , kolkata**
- **1/07/25–**

EDUCATION :

MBBS(1999–2005)

NRS Medical College, Kolkata

MD (Radiotherapy - Clinical Oncology) (2008–2011)

SSKM & IPGMER, Kolkata

DrNB (Medical Oncology) (2019–2022)

Tata Medical Centre, Kolkata

MRCP (UK, SCE Medical Oncology) (2022)

Federation of Royal Colleges of Physicians, UK

ECMO (Medical Oncology) (October 2023)

European Society for Medical Oncology (ESMO)

PREVIOUS POSITION

Clinical director oncology service and Consultant Hemato-Medical Oncologist

B P Poddar Hospital & Medical Research Ltd, Kolkata

Since: 01 September 2022 –20/06/25

Consultant Clinical Oncologist

Narayana Multispeciality Hospital, Barasat, WB

Visiting Radiation Oncologist

Narayana Superspeciality Hospital, Howrah, WB

Consultant Clinical Oncologist

Sanjiban Hospital, Howrah, WB

Clinical Tutor (WBMES)

Department of Clinical Oncology

May 2013 – March 2018

Senior Resident

Dept. of Medical Oncology, Chittaranjan National Cancer Research Institute, Kolkata , May 2011 – April 2013

Junior Resident

Dept. of Chest Medicine, Medical College

July 2007 – April 2008

Junior resident

ICU , Shree jain hospital howrah , 2005-2007

CLINICAL STUDY PARTICIPATION

Principal Investigator:

1. **C2A03229** – A double-blind, multicenter, randomized bioequivalence study of Olaparib Tablets (Natco Pharma) vs. Lynparza Tablets (AstraZeneca) in ovarian, breast, or prostate cancer patients.
2. **C2A03014** – Bioequivalence study of Olaparib Tablets (Natco Pharma) vs. Lynparza Tablets (AstraZeneca) under fasting conditions in cancer patients.
3. **CA-170-302A** – Phase IIb/III randomized, double-blind study of CA-170 with chemotherapy in Stage IV non-squamous non-small cell lung cancer.
4. **BIO-PERTUZ-301** – Phase III randomized study comparing biosimilar PERT-IJS with EU-Perjeta® in HER2-positive early-stage or locally advanced breast cancer.

5. **61186372COR3002** : A Randomized, Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With KRAS/NRAS and BRAF Wildtype Recurrent, Unresectable or Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy
PUBLICATION

Early Metabolic Syndrome in Testicular Germ Cell Tumors: A Prospective Study from India

Journal of Clinical Oncology, June 2022

[DOI:10.1200/JCO.2022.40.16_suppl.e17010](https://doi.org/10.1200/JCO.2022.40.16_suppl.e17010)

High-sensitivity C-reactive Protein as Prognostic and Predictive Marker in Metastatic Non-small Cell Lung Carcinoma

Journal of Clinical Oncology, June 2022

[DOI:10.1200/JCO.2022.40.16_suppl.e21101](https://doi.org/10.1200/JCO.2022.40.16_suppl.e21101)

Perspective of Oncology Patients During COVID-19 Pandemic: A Prospective Observational Study from India

Journal of Global Oncology, June 2020

[DOI: 10.1200/GO.20.00172](https://doi.org/10.1200/GO.20.00172)

An Audit of Gastrointestinal Stromal Tumors from a Tertiary Medical College Hospital in Eastern India

Asian Journal of Oncology, January 2018

[DOI:10.4103/ASJO.ASJO_17_18](https://doi.org/10.4103/ASJO.ASJO_17_18)

Certifications and Training

ICH-GCP Certification (01-Jun-2024)

Completed training in ICH-Good Clinical Practice (ICH-GCP) under the NIDA Clinical Trials Network.

Handwritten signature and date:
3/14/24